London, October 8th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that in collaboration with King’s College London and Guys & St Thomas’ Hospitals, it has commenced a mechanistic study to noninvasively assess PD-L1 expression using 99mTc-NM-01 as a SPECT/CT radiotracer.

Professor Gary Cook, Professor of PET Imaging at King’s College London said, “We have scanned our first participant; the images I reviewed are of excellent quality and clearly show the heterogeneity of PD-L1 expression between tumours”.

Paul Edwards, Nanomab’s CEO commented, “This mechanistic study is a precursor to the Phase II

Clinical Study which we plan to commence early next year, having submitted our application to the MHRA last month. Our goal is to develop NM-01 as a common and affordable tool to enable non-invasive in vivo imaging. This would allow the measurement of PD-L1 expression before, during and after treatment within one to two hours from injection, which would provide clinicians with valuable information for patients’ treatment regime and disease progression. This could potentially be the best companion diagnostic for immune checkpoint drugs. The submission of this protocol is a significant step forward for NanoMab”

We also continue to make strong progress with NM-02, a therapeutic product for the treatment of HER2 positive cancers. We anticipate commencing an FIH study over the next 3-6 months with the aim of starting a Clinical Study Protocol in the next 12 months.


For more information:

Paul Edwards. Tel: +44 (0)7771 575374



Richard Hayhurst/Janet Joy RHApr Tel: +44 (0)7711 821 527 or



Notes to editors


NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of radiopharmaceuticals. Our goal is to develop a pipeline of theranostics with our proprietary camelid antibody platform to address the unmet medical need for cancer patients across the world.